Rigel Pharmaceuticals Inc (RIGL)
7.78
+0.05
(+0.65%)
USD |
NASDAQ |
Jul 05, 16:00
7.795
+0.02
(+0.19%)
After-Hours: 20:00
Rigel Pharmaceuticals Research and Development Expense (Annual): 24.52M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.52M |
| December 31, 2022 | 60.27M |
| December 31, 2021 | 65.24M |
| December 31, 2020 | 60.10M |
| December 31, 2019 | 52.88M |
| December 31, 2018 | 46.90M |
| December 31, 2017 | 46.27M |
| December 31, 2016 | 63.45M |
| December 31, 2015 | 62.82M |
| December 31, 2014 | 67.70M |
| December 31, 2013 | 75.33M |
| December 31, 2012 | 78.78M |
| December 31, 2011 | 69.35M |
| Date | Value |
|---|---|
| December 31, 2010 | 64.39M |
| December 31, 2009 | 90.74M |
| December 31, 2008 | 109.67M |
| December 31, 2007 | 70.36M |
| December 31, 2006 | 56.97M |
| December 31, 2005 | 52.04M |
| December 31, 2004 | 48.52M |
| December 31, 2003 | 43.36M |
| December 31, 2002 | 43.35M |
| December 31, 2001 | 32.31M |
| December 31, 2000 | 32.03M |
| December 31, 1999 | 17.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
24.52M
Minimum
2023
65.24M
Maximum
2021
52.60M
Average
60.10M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Ardelyx Inc | 35.54M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |
| Theriva Biologics Inc | 14.31M |